Search all CIRM Grants
Information about disease focus, human stem cell use or new cell line generation will typically not be available on the website until a few months after the award is announced. Disease categories are provided for awards that might impact a given disease or related area, whether those awards are for translational research on new therapy candidates or for basic research to address a biological question that is relevant to that disease.
| Institution | Researcher name | Grant Type | Grant Title | ICOC Approved Funds |
|---|---|---|---|---|
| ViaCyte, Inc. | Allan Robins | Disease Team Research I | Cell Therapy for Diabetes | $22,999,937 |
| ViaCyte, Inc. | Howard Foyt | Strategic Partnership I | Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes | $10,075,070 |
| ViaCyte, Inc. | Emmanuel Baetge | Disease Team Planning | Development of a Cell Replacement Therapy Product for Insulin Dependent Diabetes | $48,950 |
| ViaCyte, Inc. | Evert Kroon | Tools and Technologies I | Development of the Theracyte Cellular Encapsulation System for Delivery of human ES Cell-derived Pancreatic Islets and Progenitors. | $827,072 |
| ViaCyte, Inc. | Olivia Kelly | Early Translational I | Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product | $5,405,397 |
Total: $39,356,426.00 |
